Irbesartan+hidroclorotiazida Fisiofen

Irbesartan/Hydrochlorothiazide, the active ingredient in Irbesartan+hidroclorotiazida Fisiofen, is an angiotensin II receptor blocker / thiazide diuretic presented as an oral tablet for oral use. It is used to lower high blood pressure in adult patients.

GNH USA supplies Irbesartan+hidroclorotiazida Fisiofen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan/Hydrochlorothiazide is indicated for the management of hypertension, a condition characterized by elevated arterial pressure.

- Hypertension: lowers systolic and diastolic blood pressure, helping to reduce cardiovascular risk.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Increased urination - Mild electrolyte disturbances (e.g., low potassium)

Serious or Rare Side Effects: - Severe dehydration or electrolyte imbalance - Allergic reactions such as rash or angioedema - Acute kidney injury or worsening renal function - Significant hypotension - Blood disorders such as agranulocytosis

Patients should be monitored regularly while taking this combination therapy. - Blood pressure monitoring: ensure target levels are achieved without excessive drop. - Renal function assessment: check serum creatinine and eGFR periodically. - Electrolyte balance: monitor potassium and sodium levels, especially with diuretic component. - Hepatic impairment: use with caution in patients with liver disease. - Pregnancy and lactation: safety not established; avoid unless clearly needed. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan/Hydrochlorothiazide may interact with several medicines.

Major Interactions (Avoid): - ACE inhibitors or potassium‑sparing diuretics: risk of hyperkalaemia. - NSAIDs: may blunt antihypertensive effect and affect renal function. - Lithium: increased lithium levels and toxicity.

Moderate Interactions (Monitor Closely): - Other antihypertensives (e.g., beta‑blockers): additive blood‑pressure lowering. - Antidiabetic agents: may require dose adjustment due to diuretic‑induced glucose changes. - CYP2C9 inhibitors (e.g., fluconazole): may raise irbesartan concentrations.